The discovery in 2004 that activating somatic mutations in the tyrosine kinase EGFR gene make the tumor sensitive to tyrosine kinase inhibitors (TKIs) treatment has represented one of the most significant breakthrough in the field of molecular oncology in the past decade [1,2]. The gene discussed is EGFR; the disease is neoplasm.